Key Highlights
- GRAIL’s novel risk classification test on its Methylation Platform extends to Japan, in collaboration with AstraZeneca.
- The test supports early, non-invasive detection of Stage I lung adenocarcinoma without the need for tumor tissue.
- Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL, emphasizes the test’s role in advancing precision oncology with a tissue-free, blood-only methodology.
Source: Business Wire
Notable Quote
- “GRAIL’s tissue-free, blood-only methodology is designed to aid in clinical trial selection with potential for customizable diagnostic approaches that can enable precision oncology.” – Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL
SoHC's Take
This collaboration between GRAIL, LLC and AstraZeneca represents a pivotal step forward in the fight against cancer. By integrating GRAIL’s innovative Methylation Platform for risk classification into AstraZeneca’s clinical trials in Japan, this partnership aims to refine the approach to cancer detection and treatment. The ability to detect cancer early, particularly Stage I lung adenocarcinoma, without relying on tumor tissue samples, is a breakthrough in precision oncology. This method not only promises to streamline clinical trial selection but also to personalize patient care through customizable diagnostic solutions. The strategic partnership further underscores the commitment of both organizations to leverage cutting-edge technology in improving patient outcomes and advancing the field of oncology. With GRAIL’s mission to detect cancer early and AstraZeneca’s global reach in pharmaceuticals, this collaboration is poised to make significant contributions to cancer care worldwide.
